{
    "title": "Novartis buoyed by trial success in early-stage breast cancer",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11906255/Novartis-buoyed-trial-success-early-stage-breast-cancer.html",
    "date": "2023-03-27",
    "keywords": [
        "trial",
        "drug",
        "cancer",
        "growth",
        "kisqali",
        "breast",
        "risk",
        "recurrence",
        "market",
        "benefit",
        "analyst",
        "burger",
        "confidence",
        "boost",
        "therapy",
        "firm",
        "approval",
        "side",
        "novartis",
        "year",
        "key",
        "comment",
        "industry",
        "background",
        "stage",
        "disease",
        "monday",
        "high",
        "gmt",
        "panel",
        "analysis",
        "latestage",
        "type",
        "response",
        "endocrine",
        "body",
        "share",
        "ibrance",
        "earlierstage",
        "verzenio",
        "setting",
        "surgery",
        "highrisk",
        "everything",
        "efficacy",
        "effect",
        "profile",
        "le",
        "berrigaud",
        "update",
        "executive",
        "vas",
        "narasimhan",
        "core",
        "income",
        "margin",
        "unit",
        "sandoz",
        "half",
        "company",
        "reliant",
        "development",
        "role",
        "blood",
        "disorder",
        "astrazenecas",
        "soliris",
        "conference",
        "meeting",
        "timing",
        "world",
        "wider",
        "use",
        "reporting",
        "heine",
        "clarence",
        "fernandez"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}